• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Alzheimer's disease

Biogen
Biotech

Biogen’s tau drug drives bigger benefits in Alzheimer’s update

Biogen saw a further slowing of clinical decline after two years, leading analysts to hail the strengthening of evidence for late-phase development.
Nick Paul Taylor Nov 18, 2026 9:26am
Brain scan neuroscience

Priavoid’s Alzheimer’s pill fails to prove efficacy in ph. 2

Nov 18, 2026 4:21am
alzheimers brain neurodegenerative memory head

Cognito phase 3 flops in AD trial, but sees ‘signal’ for HOPE

Nov 18, 2026 3:23am
colorful brain art model
Favicon Fierce Pharma

AriBio’s oral Alzheimer’s drug meets monotherapy goal in ph. 3

Nov 17, 2026 7:43am
Lilly

Lilly scraps ph. 2 Alzheimer's program after drug falls short

Oct 29, 2026 2:09pm
positive negative up down good bad mixed

Acadia misses mark in Alzheimer’s but continues phase 3 program

Sep 24, 2026 9:46am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings